Videos
Frequency of TECVAYLI (teclistamab) Administration for Myeloma Patients
In this week's Ask Dr. Durie, IMF Chief Scientific Officer and multiple myeloma expert Dr. Brian G.M. Durie discusses a recent real-world analysis of Teclistamab, an anti-BCMA bispecific antibody approved by the FDA. The…
News Article
The International Myeloma Foundation Thanks Dr. Brian G.M. Durie for 35 Years of Remarkable Leadership
Assembles Global Dream Team and Establishes Scientific Advisory Board to Accelerate Myeloma Research
STUDIO CITY, CA, July 3, 2024—The International Myeloma Foundation (IMF) today…
Page
The IMF has culled the best information from external resources and peer organizations to help guide you through your caregiving journey: The Cancer Caregiver Podcast "is for the…
Page
The picture of medical coverage for a patient varies on a case-by-case basis, and navigating the cost of care often falls in the hands of care partners. While some patients have private insurance, others are on state-administered plans. Some may be on…
Page
Maybe you are a parent with young children or teens, or a spouse or partner who must share your myeloma diagnosis with your loved one. Talking about cancer is never easy, but it is always necessary. The following links provide options on how to share your diagnosis with your loved ones, as well as…
Page
Maybe you need help with household chores or cooking. Perhaps you need a better way to track your loved one's medical records. The following resources will help you on your care partner journey:
An IMF presentation on…
Page
Caregivers, or care partners, often feel overly taxed by their duties. Remember, once you board a plane, you are always advised to put on your oxygen mask first before assisting your loved ones. The same rule is true for care partners. Listed here are some resources that will help you 'catch…
Audio
Hip. Hope. Hooray! Men Talkin' Health
Myeloma survivor, advocate, and Founder of the Health, Hope, & Hip-Hop Foundation, Oya Gilbert, creates a dynamic space for men to share their health stories, struggles, and successes. Each episode features real conversations with men from all walks of…
Videos
Abstract Title:
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma: Interim Analysis of the GMMG-HD7 Trial
Summary:
The GMMG-HD7 trial evaluated the efficacy of adding isatuximab (Isa) to…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the June 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Abstract Title:
A Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 FASTCAR-T (GC012F) as First-Line Therapy for Transplanteligible Newly Diagnosed High-Risk Multiple Myeloma
Summary:
This abstract presents the results of a phase I study…
Videos
Four-Drug Combinations for Older Transplant Ineligible Myeloma Patients
In this week's Ask Dr. Durie, IMF Chief Scientific Officer and multiple myeloma expert Dr. Brian G.M. Durie addresses a question about the recommendation of four-drug combinations for elderly myeloma patients who are not…
Videos
Abstract Title:
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma: Interim Analysis of the GMMG-HD7 Trial
Summary:
The GMMG-HD7 trial evaluated the efficacy of adding isatuximab (Isa) to…
Videos
Abstract Title:
Class comparison of BCMA-directed therapies in relapsed multiple myeloma
Summary:
This retrospective study evaluated the efficacy of BCMA-directed therapies in relapsed multiple…
Videos
Abstract Title:
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of…
Videos
Abstract Title:
Efficacy, Safety, and Determination of RP2D of ABBV-383, a BCMA Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Summary:
The phase 1 trial of ABBV-383, a BCMA bispecific antibody, in patients with…
Page
Myeloma and myeloma treatment can lead to changes that affect the eyes (ocular toxicity) ranging from how well a person can see (visual acuity) to tissue damage (i.e. corneal, retinal). Often, these changes are temporary, may continue until treatment is received, or may only occur while on a…
Videos
Abstract Title:
Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Depth and Durability of Response at 14-Month Median Follow-Up
Summary:
The study evaluated the efficacy and safety of linvoseltamab, a B-cell…
Videos
Effects of FDA Approval of MRD testing for Myeloma on Patients and Drug Development
In this week's Ask Dr. Durie, IMF Chief Scientific Officer and multiple myeloma expert Dr. Brian G.M. Durie discusses the recent FDA approval of MRD (minimal residual disease) testing as an early endpoint for…
Page
Cytokine release syndrome (CRS) is a condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. Cytokines are small proteins that play a crucial role in regulating immune responses and inflammation. In normal…
Videos
Abstract Title:
Idecabtagene Vicleucel (ide-cel) in Patients (Pts) with Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Frontline (1L) Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2b
Summary:
KarMMa-2 is a multicohort, phase…
Videos
Global Collaboration Thrives at the IMF's 2024 Global Myeloma Action Network's Annual Summit
At its Global Myeloma Action Network (GMAN) annual summit from June 7-9, 2024, in Madrid, Spain, the International Myeloma Foundation (IMF) brought together patient advocates from over 40 myeloma…
News Article
June 24, 2024 — The International Myeloma Foundation is proud to announce that its strong financial health and ongoing accountability and transparency has earned a Four-Star Rating from Charity Navigator. This rating designates the International Myeloma…
Videos
Abstract Title:
Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) versus VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)
Summary:
The Phase 3 IMROZ study compared the efficacy…
News Article
"I Have Insurance, Why Can't I Afford My Oral Anticancer Medications?" International Myeloma Foundation Highlights the Urgent Need for Cancer Drug Parity Act at Congressional Briefing
The Successful Briefing Addressed Insurance Coverage for Oral Anticancer Medications
Washington…
Videos
Abstract Title:
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Summary:
The DREAMM-…
Videos
Abstract Title:
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus Isa-Rd in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
Summary:
This abstract summarizes…
Videos
Abstract Title:
Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial
Summary:
The PERSEUS…
News Article
Global Collaboration Thrives at the IMF's 2024 Global Myeloma Action Network's Annual Summit
At its Global Myeloma Action Network (GMAN) annual summit from June 7-9, 2024, in Madrid, Spain, the International Myeloma Foundation (IMF) brought together 100 of the greatest minds in myeloma. The…
Videos
IMF's 15th Annual Gala Raised Nearly $700K to Support Myeloma Research
Together, we raised nearly $700,000 to benefit the Peter Boyle Research Fund, the IMF’s Black Swan Research Initiative®, and our educational programs. This significant contribution will accelerate groundbreaking myeloma…
Videos
Abstract title:
Cevostamab in Patients with RRMM Who Are Triple-Class Refractory and Have Received a Prior BCMA-Targeted ADC or CAR T-Cell: Initial Results from the Phase I/II CAMMA 2 Study
Summary:
Cevostamab, a FcRH5xCD3 bispecific antibody, has shown…
Videos
Myeloma Treatment with Bispecific Antibody Targets
Myeloma Made Simple: Bispecific Antibody Targets Made Simple
In this episode of Myeloma Made Simple, we explore how immunotherapy fights myeloma using the body's own defenses. Bispecific antibodies, the focus of this video, are drugs that…
News Article
International Myeloma Foundation (IMF) to Honor 2024 Kyle and Durie Achievement Awardees, Dr. Shaji Kumar and Dr. Francesca Gay
Awarding ceremonies to be held on June 11 at the 15th Annual IMWG Summit in Madrid, Spain
MADRID, SPAIN, June 11, 2024—The…
Page
In this series, IMF Chief Medical Officer Dr. Joseph Mikhael breaks down the complexities of myeloma into simple, easy-to-follow explanations. Whether it's about diagnosis, treatment options, or the latest research, Dr. Mikhael's approachable to difficult concepts helps patients, care partners, and…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the May 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Audio
An Interview with Myeloma Patient and Care Partner Adrienne and Chad Moore
Their insights on dealing with a multiple myeloma diagnosis as a patient and care partner team
In this episode of "A Day in the Life," Adrienne and Chad Moore, a patient and care partner…
Myeloma Made Simple: Bispecific Antibodies Made Simple | Bispecific Antibodies for Myeloma Treatment
Videos
Bispecific Antibodies for Myeloma Treatment
Myeloma Made Simple: Bispecific Antibodies Made Simple
Bispecific Antibodies Made Simple! Learn about bispecific antibodies, a cutting-edge class of drugs in myeloma treatment, designed to harness the patient's immune system to combat the disease…
News Article
According to a press release from Sanofi, "The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd…
Videos
Managing Myeloma Side Effects with Xpovio (Selinexor)
Myeloma Made Simple: Selinexor Side Effect Management Made Simple
Selinexor Side Effect Management Made Simple! In this video, IMF Chief Medical Officer Dr. Joseph Mikhael discusses the latest insights on Xpovio® (Selinexor…
Videos
Virtual Multiple Myeloma Community Workshop
A virtual multiple myeloma workshop addressing the needs specific to communities in the Mid Atlantic region of the United States.
The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at…
News Article
International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma
Twelve Student-Mentor Pairs to Participate in 2024 NMA Annual Convention and Scientific Assembly in August
The International Myeloma Foundation (IMF) is proud to…
Videos
Selinexor for Multiple Myeloma Treatment
Myeloma Made Simple: Xpovio (Selinexor) Made Simple
Xpovio (Selinexor) Made Simple! Join Dr. Joseph Mikhael to learn about Xpovio® (Selinexor), a drug in the treatment of myeloma that belongs to a new class of drugs called XPO1 inhibitors.…
Videos
The Role of ASCT in the Frontline Setting for African-American Patients
In this week's episode of Ask Dr. Durie, myeloma expert Dr. Brian G.M. Durie discusses the role of ASCT in the frontline setting for African-American patients.
Immune therapies like CAR T-cell therapy are being…
News Article
On Thursday, April 25, Nurse Leadership Board (NLB) members Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, BMTCN®, FAAN, FAPO; Kevin Brigle, PhD, NP; Patricia Mangan, RN, MSN, APRN-BC; and Donna Catamero, ANP-BC, OCN presented Case Studies for Nurses: New and Therapies and Regimens for Patients With…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the April 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Does MGUS Require Bone Marrow Testing?
A new study from Iceland, part of the IMF's iStopMM project, distinguishes between patients who require bone marrow testing and those who can be safely monitored without immediate bone marrow testing.
The study accurately predicted that…
News Article
Patient Advocates Meet with Legislators
YOU can help ensure that research of myeloma and other cancers receives adequate funding
By Emma Hatcher, IMF Global Vice President, Patient Engagement & Advocacy
Have you ever thought about how you can help…
News Article
With Over $675,000 Raised, the Gala Benefits the Peter Boyle Research Fund and Celebrates Groundbreaking Myeloma Research, Education, Support, and Advocacy
STUDIO CITY, Calif. April 25, 2024—On Thursday, April 18, The International Myeloma Foundation (IMF) held…